Gün Eylül, Çakır İzzetiye Ebru, Ersöz Hasan, Oflazoğlu Utku, Sertoğullarından Bünyamin
Department of Cellular Pathology, Basildon & Thurrock University Hospital, Mid and South Essex NHS Foundation Trust, Basildon, Essex, United Kingdom.
Department of Pathology, İzmir Katip Çelebi University Atatürk Training and Research Hospital, İzmir, Turkey.
Thorac Res Pract. 2024 Feb 8;25(3):102-109. doi: 10.5152/ThoracResPract.2024.23067.
The management of non-small cell lung carcinomas (NSCLC) has changed with the identification of molecular pathways. We aimed to reveal the 3-year epidermal growth factor (EGFR), anaplastic lymphoma kinase (ALK), and ROS proto-oncogene 1 (ROS1) mutation profile in the Turkish population. The histopathological and molecular data of all NSCLC cases from our department between May 2019 and April 2022 were evaluated. Molecular testing was performed in 197 NSCLC cases, and results were obtained in 182 (92.4%) (M/F: 144/38, aged 39-86). Of these, 121 were diagnosed with adenocarcinoma, 36 with squamous cell carcinoma, and 25 with NSCLC-not otherwise specified. The EGFR mutation was seen in 21 (11.5%) cases (6 exon 19 deletions, 3 exon 18 [all codon 719], 2 exon 20, 8 exon 21 point mutations, 1 concurrent exon 19 deletion and exon 20 codon 790 M point mutation, and 1 concurrent exon 19 deletion and exon 21 point mutation). The double mutation rate of EGFR was 1.1%. The mean age of these patients was 63.4 (40-79), with 24% of all females (n = 9) and 8.3% of all males (n = 12). The ALK mutation was detected in 6 (3.3%) patients (M/F: 4/2, aged 45-82), whereas the ROS1 mutation was detected in 3 (1.7%) (M/F: 2/1, aged 40-64). It is well established in the literature that EGFR-activating mutation rates vary depending on regions and ethnic groups. We concluded that the EGFR-activating mutation rates of the Turkish population are similar to the European molecular data instead of the Asian. The ALK and ROS1 mutation rates also seem concordant with the literature.
随着分子通路的确定，非小细胞肺癌（NSCLC）的治疗发生了变化。我们旨在揭示土耳其人群中3年表皮生长因子（EGFR）、间变性淋巴瘤激酶（ALK）和ROS原癌基因1（ROS1）的突变情况。对2019年5月至2022年4月期间我院所有NSCLC病例的组织病理学和分子数据进行了评估。对197例NSCLC病例进行了分子检测，182例（92.4%）获得了结果（男/女：144/38，年龄39 - 86岁）。其中，121例诊断为腺癌，36例为鳞状细胞癌，25例为非小细胞肺癌（未另行说明）。21例（11.5%）病例检测到EGFR突变（6例19外显子缺失，3例18外显子[均为密码子719]，2例20外显子，8例21外显子点突变，1例同时存在19外显子缺失和20外显子密码子790M点突变，1例同时存在19外显子缺失和21外显子点突变）。EGFR双突变率为1.1%。这些患者的平均年龄为63.4岁（40 - 79岁），占所有女性的24%（n = 9），所有男性的8.3%（n = 12）。6例（3.3%）患者检测到ALK突变（男/女：4/2，年龄45 - 82岁），而3例（1.7%）检测到ROS1突变（男/女：2/1，年龄40 - 64岁）。文献中已明确表明，EGFR激活突变率因地区和种族而异。我们得出结论，土耳其人群的EGFR激活突变率与欧洲分子数据相似，而非亚洲。ALK和ROS1突变率似乎也与文献一致。
